Hugin, Kolumne

Ad hoc announcement pursuant to Art.

17.04.2024 - 07:05:07

GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting. 53 LR * Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company website * Bondholder meeting now planned for early May as the company continues to engage with bondholders Allschwil, Switzerland - April 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that its Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting is available on the company website at the following link: http://www.idorsia.com/investors/financial-information Idorsia continues to engage with bondholders on options and terms regarding the repayment of the convertible bond maturing on July 17, 2024 (ISIN: CH0426820350).

Ad hoc announcement pursuant to Art. 53 LR
  * Unaudited Financial Status as of March 31, 2024, required for an upcoming
    bondholder meeting, now available on the company website
  * Bondholder meeting now planned for early May as the company continues to
    engage with bondholders
Allschwil, Switzerland - April 17, 2024
Idorsia Ltd (SIX: IDIA) today announced that its Unaudited Financial Status as
of March 31, 2024, required for an upcoming bondholder meeting is available on
the company website at the following link:
http://www.idorsia.com/investors/financial-information
Idorsia continues to engage with bondholders on options and terms regarding the
repayment of the convertible bond maturing on July 17, 2024 (ISIN:
CH0426820350). As a result, the bondholder meeting initially contemplated for
April 30, 2024, is expected to take place shortly thereafter.
André C. Muller, Chief Financial Officer, commented:
"We have had many interactions with our bondholders in the past week. We are
finalizing our proposed amendment to the terms and conditions of the bond,
taking into account the bondholder needs as well as our objective to avoid
unnecessary dilution. We expect to publish the invitation to the bondholders
meeting in the next few days."
Notes to the editor
About Idorsia
Idorsia Ltd is reaching out for more - We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve this, we
will develop Idorsia into a leading biopharmaceutical company, with a strong
scientific core.
Headquartered near Basel, Switzerland - a European biotech-hub - Idorsia is
specialized in the discovery, development and commercialization of small
molecules to transform the horizon of therapeutic options. Idorsia has a 25-year
heritage of drug discovery, a broad portfolio of innovative drugs in the
pipeline, an experienced team of professionals covering all disciplines from
bench to bedside, and commercial operations in Europe and North America - the
ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017
and has over 750 highly qualified specialists dedicated to realizing our
ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com (mailto:investor.relations@idorsia.com)
media.relations@idorsia.com (mailto:media.relations@idorsia.com)
www.idorsia.com (http://www.idorsia.com)
The above information contains certain "forward-looking statements", relating to
the company's business, which can be identified by the use of forward-looking
terminology such as "estimates", "believes", "expects", "may", "are expected
to", "will", "will continue", "should", "would be", "seeks", "pending" or
"anticipates" or similar expressions, or by discussions of strategy, plans or
intentions. Such statements include descriptions of the company's investment and
research and development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the company
and anticipated customer demand for such products and products in the company's
existing portfolio. Such statements reflect the current views of the company
with respect to future events and are subject to certain risks, uncertainties
and assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future results,
performances or achievements that may be expressed or implied by such forward-
looking statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected.
Â
@ dpa.de

Weitere Meldungen

GNW-Adhoc: eGain im Gartner® Market Guide 2024 für Kundendienst-Wissensmanagementsysteme als repräsentativer Anbieter ausgezeichnet SUNNYVALE, Kalifornien, June 14, 2024 (GLOBE NEWSWIRE) -- eGain Corporation (NASDAQ: EGAN (http://www.nasdaq.com/symbol/egan)), die KI-Wissensplattform für den Kundendienst, hat heute bekanntgegeben, dass sie im ?Gartner Market Guide 2024 for Customer Service Knowledge Management Systems" aufgeführt wird. (Boerse, 14.06.2024 - 18:28) weiterlesen...

GNW-Adhoc: Vertex erwirbt Steuerfähigkeiten im Bereich der künstlichen Intelligenz von Ryan, LLC KING OF PRUSSIA, Pennsylvania, June 14, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (Boerse, 14.06.2024 - 08:35) weiterlesen...

GNW-Adhoc: Lantronix gewinnt IoT Evolution Asset Tracking Award 2024 für FOX3 Telematik-Gateway IRVINE, Kalifornien, June 13, 2024 (GLOBE NEWSWIRE) -- Lantronix Inc. (Boerse, 13.06.2024 - 23:00) weiterlesen...

GNW-Adhoc: OBI Pharma gibt Beginn einer Phase-I/II-Studie zu OBI-992 bekannt, ein auf TROP2 ausgerichtetes Antikörper-Wirkstoff-Konjugat (AWK) zur Krebstherapie TAIPEI, Taiwan, June 13, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, ein im klinischen Stadium tätiges Onkologieunternehmen (4174.TWO), hat heute den Beginn einer klinischen Phase-I/II-Studie zu OBI-992 bekanntgegeben, einem Antikörper- Wirkstoff-Konjugat (AWK), das auf TROP2 (Trophoblasten-Zelloberflächen-Antigen 2) abzielt, ein Antigen, das bei verschiedenen Tumorarten überexprimiert wird. (Boerse, 13.06.2024 - 06:49) weiterlesen...

GNW-Adhoc: QIAGEN veröffentlicht Nachhaltigkeitsbericht 2023 und hebt Fortschritte bei ESG-Zielen sowie Engagement für nachhaltiges Wachstum hervor VENLO, Niederlande, June 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute seinen Nachhaltigkeitsbericht 2023 veröffentlicht, der das Engagement des Unternehmens in den Bereichen Umwelt, Soziales und Governance (ESG) unterstreicht und wichtige Erfolge auf seinem Weg zu mehr Nachhaltigkeit hervorhebt. (Boerse, 12.06.2024 - 22:10) weiterlesen...

GNW-Adhoc: Rackspace Technology als führend im Frost Radar: Healthcare Enterprise Cloud Managed Services Providers, 2024 für Wachstumspotenzial und Innovation von Gesundheitsunternehmen anerkannt SAN ANTONIO, June 12, 2024 (GLOBE NEWSWIRE) -- Rackspace Technology® (NASDAQ: RXT) - das führende Unternehmen für End-to-End-, hybride Multi-Cloud- und KI- Lösungen, hat heute bekanntgegeben, dass Rackspace im Frost Radar für Healthcare Enterprise Cloud Managed Service Provider, 2024, als ?führend" eingestuft wird. (Boerse, 12.06.2024 - 19:04) weiterlesen...